Cancer fatigue: A neurobiological review for psychiatrists

Psychosomatics

Volumn 49, Issue 4, 2008, Pages 283-291

  Levy, Mitchell R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYTOKINE; DOPAMINE; GAMMA INTERFERON; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; KYNURENINE; METHYLPHENIDATE; NORADRENALIN; OMEGA 3 FATTY ACID; PROSTAGLANDIN INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ANHEDONIA; ANOREXIA; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CIRCADIAN RHYTHM; COGNITIVE DEFECT; CULTURAL FACTOR; CYTOKINE RESPONSIVE ELEMENT; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FATIGUE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GUILT; HOPELESSNESS; HUMAN; HYPERALGESIA; ILLNESS BEHAVIOR; LIBIDO DISORDER; MENTAL HEALTH CARE; NEUROBIOLOGY; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PREVALENCE; PSYCHIATRIST; PSYCHOMOTOR RETARDATION; REVIEW; SCREENING; SLEEP DISORDER; SOCIAL ISOLATION; SUICIDAL IDEATION; SYMPTOMATOLOGY; WEIGHT REDUCTION;

EID: 46149106580     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.49.4.283     Document Type: Review

References (136)

1. Cella D, Lai JS, Chang CH, et al: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94:528-538
2. Passik SD, Kirsh KL, Donaghy K, et al: Patient-related barriers to fatigue communication: initial validation of The Fatigue Management Barriers Questionnaire. J Pain Symptom Manage 2002; 24:481-493
3. Prue G, Rankin J, Allen J, et al: Cancer-related fatigue: a critical appraisal. Eur J Cancer 2006; 42:846-863 (E-pub: Feb. 7, 2006)
4. Jacobsen PB, Donovan KA. Cancer and fatigue: insights from studies of women treated for breast cancer. in Fatigue as a Window to the Brain. Edited by DeLuca J. Cambridge, MA, MIT Press, 2005, pp 265-280
5. Jacobsen PB, Hann DM, Azzarello LM, et al: Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999; 18:233-242
6. Donovan KA, Jacobsen PB, Andrykowski MA, et al: Course of fatigue in women receiving chemotherapy and/or radiotherapy for early-stage breast cancer. J Pain Symptom Manage 2004; 28:373-380
7. Geinitz H, Zimmermann FB, Stoll P, et al: Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Physiol 2001; 51:691-698
8. Gaston-Johansson F, Fall-Dickson JM, Bakos AB, et al: Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Pract 1999; 7:240-247
9. Hann DM, Garovoy N, Finkelstein B, et al: Fatigue and quality of life in breast cancer patients undergoing autologous stem-cell transplantation: a longitudinal comparative study. J Pain Symptom Manage 1999; 17:311-320
10. Jacobsen PB, Hann DM, Azzarello LM, et al: Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course and correlates. J Pain Symptom Manage 1999; 19:14-27
11. Jacobsen PB, Garland LL, Booth-Jones M, et al: Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004; 28:7-18
12. Hann DM, Jacobsen PB, Martin S, et al: Fatigue and quality of life following radiotherapy for breast cancer: a comparative study. J Clin Psychol Med Set 1998; 5:19-33
13. Smets EMA, Visser MRM, Willems-Groot AFMN, et al: Fatigue and radiotherapy, (B): experience in patients 9 months following treatment. Br J Cancer 1998; 78:907-912
14. Servaes P, Verhagen C, Schreuder B, et al: Fatigue after treatment for malignant and benign bone and soft tissue tumors. J Pain Symptom Manage 2003; 26:1113-1122
15. Servaes P, Gielissen MF, Verhagen S, et al: The course of severe fatigue in disease-free breast cancer patients: a longitudinal study. Psychooncology 2007; 16:787-795
16. Berglund G, Bolund C, Fornander T, et al: Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 1991; 27:1075-1081
17. Greenberg DB, Sawicka J, Eisenthal S, et al: Fatigue syndrome due to localized radiation. J Pain Symptom Manage 1992; 7:38-45
18. Irvine DM, Vincent L, Graydon JE, et al: Fatigue in women with breast cancer receiving radiation therapy. Cancer Nurs 1998; 21:127-135
19. Hann DM, Jacobsen PB, Azzarello LM, et al: Measurement of fatigue in cancer patients: development and validation of The Fatigue Symptom Inventory. Qual Life Res 1998; 7:301-310
20. Broeckel JA, Jacobsen PB, Horton J, et al: Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998; 16:1689-1696
21. Hann DM, Jacobsen PB, Martin SC, et al: Fatigue in women treated with bone-marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer 1997; 5:44-52
22. Winer EP, Lindley C, Hardee M, et al: Quality of life in patients surviving at least 12 months following high-dose chemotherapy with autologous bone-marrow support. Psychooncology 1999; 8:167-176
23. Smets EMA, Visser MRM, Willems-Groot AFMN, et al: Fatigue and radiotherapy (B): experience in patients 9 months following treatment. Br J Cancer 1998; 78:907-912
24. Servaes P, van derWerf S, Prins J, et al: Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer 2000; 9:11-17
25. Dow KH, Ferrell BR, Leigh S, et al: An evaluation of quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat 1996; 39:261-273
26. Jacobsen PB, Stein K: Is fatigue a long-term side effect of breast cancer treatment? Cancer Control 1999; 6:256-263
27. Spelleden ER, Verbeek JH, Uitterhoeve AL, et al: Cancer, fatigue, and the return of patients to work: a prospective cohort study. Eur J Cancer 2003; 39:1562-1567
28. Christodoulou C: The assessment and measurement of fatigue, in Fatigue as a Window to the Brain. Edited by DeLuca J. Cambridge, MA, MIT Press, 2005, pp 19-36
29. Riese X: Fatigue as a window to the brain, in Fatigue: Its Definition, Its Study, and Its Future. Edited by DeLuca J. Cambridge, MA, MIT Press, 2005, pp 319-326
30. van der Linden D, Frese M, Meijman TF: Mental fatigue and the control of cognitive processes: effects on perseveration and planning. Acta Psychol (Amsterdam) 2003; 113:45-65
31. Chiaravalloti ND, Demaree H, Gaudino EA, et al: Can the repetition effect maximize learning in multiple sclerosis? Clin Rehabil 2003; 17:58-68
32. Hann DM, Denniston MM, Baker F: Measurement of fatigue in cancer patients: further validation of The Fatigue Symptom Inventory. Qual Life Res 2000; 9:847-854
33. Piper BF, Dibble SL, Dodd MJ, et al: The Revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 1998; 25:677-684
34. Stein KD, Martin SC, Hann DM, et al: A multidimensional measure of fatigue for use with cancer patients. Cancer Pract 1998; 6:143-152
35. Servaes P, Verhagen C, Bleijenberg G: Relations between fatigue, neuropsychological functioning, and physical functioning after treatment for breast carcinoma. Cancer 2002; 95:2017-2026
36. Cella D, Davis K, Breitbart W, et al: Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19:3385-3391
37. Reuter K, Harter M: The concepts of fatigue and depression in cancer. Eur J Cancer Care (England) 2004; 13:127-134
38. Young KE, White CA: The prevalence and moderators of fatigue in people who have been successfully treated for cancer. J Psychosom Res 2006; 60:29-38
39. Maraste R, Brandt L, Olsson H, et al: Anxiety and depression in breast cancer patients at start of adjuvant radiotherapy: relations to age and type of surgery. Acta Oncol 1992; 31:641-643
40. Craig TJ, Abeloff MD: Psychiatric symptomatology among hospitalized cancer patients. Am J Psychiatry 1974; 131:1323-1327
41. Hotopf M, Chidgey J, Addington-Hall J, et al: Depression in advanced disease: a systematic review, Part 1: prevalence and case-finding. Palliat Med 2002; 16:81-97
42. McDaniel JS, Musselman DL, Porter MR, et al: Depression in the cancer patient: a commentary on diagnosis, biology, and treatment. Arch Gen Psychiatry 1995; 52:89-99
43. Endicott J: Measurement of depression in patients with cancer. Cancer 1984; 53:2243-2248
44. Leopold KA, Ahles TA, Walch S, et al: Prevalence of mood disorders and utility of the PRIME-MD in patients undergoing radiation therapy. Int J Radiat Oncol Biol Physiol 1998; 42:1105-1112
45. Kugaya A, Akechi T, Okuyama T, et al: Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 2000; 88:2817-2823
46. Goring H, Baldwin R, Marriott A, et al: Validation of short screening tests for depression and cognitive impairment in older medically ill inpatients. Int J Geriatr Psychiatry 2004; 19:465-471
47. Middelbow T, Ovesen L, Mortensen EL, et al: Depressive symptoms in cancer patients undergoing chemotherapy: a psychometric analysis. Psychother Psychosom 1994; 61:171-177
48. Leon AC, Portera L, Walkup JT: The development and evaluation of The Brief Depression Screen in medically ill disability claimants. Int J Psychiatry Med 2001; 31:389-400
49. Parker G, Hilon T, Bains J, et al: Cognitive-based measures screening for depression in the medically ill: The DMI-10 and The DMI-18. Acta Psychiatr Scand 2003; 105:419-426
50. Guo Y, Musselman DL, Manatunga AK, et al: The diagnosis of major depression in patients with cancer: a comparative approach. Psychosomatics 2006; 47:376-384
51. Reuter K, Raugust S, Bengel J, et al: Depressive symptom patterns and their consequences for diagnosis of affective disorders in cancer patients. Support Care Cancer 2004; 12:864-870 (E-pub: Oct. 9, 2004)
52. Trask PC: Assessment of depression in cancer patients. J Natl Cancer Inst Monogr 2004; 32:80-92
53. Kirsh KL, Passik S, Holtsclaw E, et al: I get tired for no reason: a single-item screening for cancer-related fatigue. J Pain Symptom Manage 2001; 22:931-937
54. Reuter K, Classen CC, Roscoe JA, et al: Association of coping style, pain, age, and depression with fatigue in women with primary breast cancer. Psychooncology 2006; 15:772-779
55. Prieto JM, Blanch J, Atala J, et al: Clinical factors associated with fatigue in hematologic cancer patients receiving stem-cell transplantation. Eur J Cancer 2006; 42:1749-1755 (E-pub: Nov 28, 2005)
56. Andrykowski MA, Curran SL, Lightner R: Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med 1998; 21:1-18
57. Raison CL, Demetrashvili M, Capuron L, et al: Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19:105-123
58. Wichers MC, Kenis G, Leue C, et al: Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006; 60:77-79 (E-pub: Feb. 17, 2006)
59. Musselman DL, Lawson DH, Gumnick JF, et al: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344:961-966
60. Wells KB, Stewart A, Hays RD, et al: The functioning and well-being of depressed patients: results from The Medical Outcomes Study. JAMA 1989; 262:914-919
61. Raison CL, Miller AH: Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003; 54:283-294
62. Yirmiya R, Weidenfeld J, Pollak Y, et al: Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv Exp Med Biol 1999; 461:283-316
63. Capuron L, Ravaud A, Dantzer R: Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2001; 63:376-386
64. Capuron L, Gumnick JF, Musselman DL, et al: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26:643-652
65. Loge JH, Abrahamsen AF, Ekeberg, et al: Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J Pain Symptom Manage 2000; 19:91-99
66. Okuyama T, Akechi T, Kugaya A, et al: Factors correlated with fatigue in disease-free breast cancer patients: application of The Cancer Fatigue Scale. Support Care Cancer 2000; 8:215-222
67. Jacobsen PB, Andrykowski MA, Thors CL: Relationship of catastrophizing to fatigue among women receiving treatment for breast cancer. J Consult Clin Psychol 2004; 72:355-361
68. McEwen BS: Stressed or stressed-out: what is the difference? J Psychiatry Neurosci 2005; 30:315-318
69. Janeway CA, Travers P, Walport M, et al: Immunobiology, 5th Edition. New York, Garland Publishing, 2001
70. Kronfol Z, Remick DG: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157:683-694
71. Wilson CJ, Finch CE, Cohen HJ: Cytokines and cognition: the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002; 50:2041-2056
72. Maier SF, Watkins LR: Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998; 105:83-107
73. Bower JE, Ganz PA, Aziz N, et al: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64:604-611
74. Greenberg DB, Gray JL, Mannix CM, et al: Treatment-related fatigue and serum interleukin-1 levels in patients during external-beam irradiation for prostate cancer. J Pain Symptom Manage 1993; 8:196-200
75. Mills PJ, Parker B, Dimsdale JE, et al: The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol Psychol 2005; 69:85-96 (E-pub: Jan 8, 2005)
76. Collado-Hidalgo A, Bower JE, Ganz PA, et al: Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006; 12:2759-2766
77. Knobel H, Loge JH, Nordoy T, et al: High level of fatigue in lymphoma patients treated with high-dose therapy. J Pain Symptom Manage 2000; 19:446-454
78. Dimeo F, Schmittel A, Fietz T, et al: Physical performance, depression, immune status, and fatigue in patients with hematological malignancies after treatment. Ann Oncol 2004; 15:1237-1242
79. Gelinas C, Fillion L: Factors related to persistent fatigue following completion of breast cancer treatment. Oncol Nurs Forum 2004; 31:269-278
80. Watkins LR, Maier SF, Goehler LE: Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci 1995; 57:1011-1026
81. Banks WA: Cytokines, CVs, and the blood-brain barrier, in Psychoneuroimmunology, 3rd Edition. Edited by Ader R, Felton DL, When N. San Diego, CA, Academic Press, 2001, pp 483-499
82. Wong ML, Bongiorno PB, Al-Shekhlee A, et al: IL-1 beta, IL-1 receptor type 1, and iNOS gene expression in rat brain vasculature and perivascular areas. Neuroreport 1996; 7:2445-2448
83. Ching S, He L, Lai W, et al: IL-1 type receptor plays a key role in mediating the recruitment of leukocytes into the central nervous system. Brain Behav Immunol 2005; 19:127-137
84. Dantzer R, Bluthe R-M, Laye S, et al: Cytokines and sickness behavior. Ann N Y Acad Sci 1998; 840:586-590
85. Wieseler-Frank J, Maier SF, Watkins LR: Central proinflammatory cytokines and pain enhancement. Neurosignals 2005; 14:166-174
86. Wrona X: Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J Neuroimmunol 2006; 172:38-58
87. Besedovsky H, del Rey A, Sorkin E, et al: Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986; 233(4764):652-654
88. Rivier C: Influence of immune signals on the hypothalamic-pituitary-axis of the rodent. Front Neuroendocrinol 1995; 16:151-182
89. Sapolsky R, Rivier C, Yamamoto G, et al: Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987; 238(4826):522-524
90. Bethin KE, Vogt SK, Muglia LJ: Interleukin-6 is an essential, corticotropin-releasing, hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA. 2000; 97(16):9317-9322
91. Owens MJ, Nemeroff CB: Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991; 43:425-473
92. Bower JE, Ganz PA, Dickerson SS, et al: Diurnal Cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005; 30:92-100
93. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49:391-404
94. Dunn AJ, Wang J, Ando T: Effects of cytokines on cerebral neurotransmission: comparison with the effects of stress. Adv Exp Med Biol 1999; 461:117-127
95. Capuron L, Ravaud A, Neveu PJ, et al: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7:468-473
96. Lestage J, Verrier D, Palin K, et al: The enzyme indolamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun 2002; 16:596-601
97. Liebau C, Baltzer AW, Schmidt S, et al: Interleukin-12 and interleukin-18 induce indolamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 2002; 22(2A):931-936
98. Zhu CB, Blakely RD, Hewlett WA: The proinflammatory cytokines interleukin 1β and tumor-necrosis factorα activate serotonin transporters. Neuropsychopharmacology 2006; 31:2121-2123
99. Bower JE, Ganz PA, Dickerson SS, et al: Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005; 30:92-100
100. Filippi M, Rocca MA, Colombo B, et al: Functional MRI correlates of fatigue in multiple sclerosis. Neuroimage 2002; 15:559-567
101. DeLuca J: Fatigue, cognition, and mental effort, in Fatigue as a Window to the Brain. Edited by DeLuca J. Cambridge, MA, MIT Press, 2005, pp 37-58
102. Tanaka H, Maeshima S, Shigekawa Y, et al: Neuropsychological impairment and decreased regional cerebral blood flow by interferon treatment in patients with chronic hepatitis: a preliminary study. Clin Exp Med 2006; 6:124-128
103. Chaudhuri A, Behan PO: Fatigue and basal ganglia. J Neurol Sci 2000; 179(suppl 1-2):34-42
104. Watkins LR, Maier SF: Glia: a novel drug-discovery target for clinical pain. Nat Rev Drug Discov 2003; 2:973-985
105. Watkins LR, Milligan ED, Maier SF: Glial activation: a driving force for pathological pain. Trends Neurosci 2001; 24:450-455
106. Sweitzer S, Martin D, DeLeo JA: Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001; 103:529-539
107. James MJ, Gibson RA, Cleland LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71(Suppl 1):343S-348S
108. Sadeghi S, Wallace FA, Calder PC: Dietary lipids modify the cytokine response to bacterial lipopolysaccharide in mice. Immunology 1999; 96:404-410
109. Raison CL, Miller AH: Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003; 54:283-294
110. Miller AH, Vogt GJ, Pearce BD: The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology 2002; 27:939-948
111. Stout SC, Owens MJ, Nemeroff CB: Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 2002; 300:1085-1092
112. Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25:43-46
113. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:63-74
114. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34:13-19
115. Nortier J, Zagari M, Vandoros C, et al: Epoetin α overcomes much of the QOL deficit seen in anemic cancer patients (Abstract 1307). Eur J Cancer 2001; 37(suppl 6):S351
116. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874
117. Senzer N: Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation. Semin Oncol 2002; 29(suppl. 6):47-52
118. Grasso G, Sfacteria A, Cerami A, et al: Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 2004; 10:93-98
119. Lande G, Cook DB, Natelson BH: Rehabilitation and treatment of fatigue, in Fatigue as a Window to the Brain. Edited by Deluca J. Cambridge, MA, MIT Press, 2005, pp 301-316
120. Cullum JL, Wojciechowski AE, Pelletier G, et al: Bupropion sustained-release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004; 49:139-144
121. Moss EL, Simpson JS, Pelletier G, et al: An open-label study of the effects of bupropion SR on fatigue, depression, and quality of life of mixed-site cancer patients and their partners. Psychooncology 2006, 15:259-267
122. Morrow GR, Shelke AR, Roscoe JA, et al: Management of cancer-related fatigue. Cancer Invest 2005; 23:229-239
123. Kubera M, Holan V, Mathison R, et al: The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology 2000; 25:785-797
124. Leonard BE: The immune system, depression, and the action of antidepressants (review). Prog Neuropsychopharmacol Biol Psychiatry 2001; 25:767-780
125. Kubera M, Maes M, Kenis G, et al: Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res 2005; 134:251-258
126. Diamond M, Kelly JP, Connor TJ: Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol 2006; 16:481-490 (E-pub: Jan. 4, 2006)
127. Yirmiya R, Pollak Y, Barak O, et al: Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001; 24:531-544
128. Sugawara Y, Akechi T, Shima Y, et al: Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002; 16:261-263
129. Sarhill N, Walsh D, Nelson KA, et al: Methylphenidate for fatigue in advanced cancer: a prospective, open-label pilot study. Am J Hospice Palliat Care 2001; 8:187-192
130. Bruera E, Valero V, Driver L, et al: Patient-controlled methyl-phenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24:2073-2078
131. Carmen P, Escalante X: Treatment of cancer-related fatigue: an update. Support Care Cancer 2003; 11:79-83
132. Rammohan KW, Rosenberg JH, Lynn DJ, et al: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two-center, phase II study. J Neurol Neurosurg Psychiatry 2002; 72:179-183
133. Berenstein EG, Ortiz Z: Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005; Apr 18:CD004310
134. Yennurajalingam S, Bruera E: Palliative management of fatigue at the close of life: "it feels like my body is just worn out." JAMA 2007; 297:295-304
135. Bruera E, Macmillan K, Hanson J, et al: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1995; 66:1279-1282
136. Amato R, Meyers C, Ellerhorst J, et al: A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol 1995; 6:911-914